摘要
目的观察利妥昔单抗(Rituximab)联合CTOP方案治疗弥漫大B细胞淋巴瘤的临床疗效及不良反应。方法 36例弥漫大B细胞淋巴瘤(diffuse large B-cell lymphoma,DLBCL)患者分为联合组和CTOP组。联合组18例,采用CTOP方案(环磷酰胺加吡喃阿霉素加长春新碱加泼尼松)加利妥昔单抗(375mg/m2,于每周期化疗前1d静脉滴注1次)治疗;CTOP组18例,单用CTOP方案化疗。两组均每21d为一个周期,6周期后评价的疗效及不良反应,随访观察生存情况。结果联合组完全缓解率(CR)为55.6%,总有效率为88.9%;CTOP组分别为38.9%,61.1%,两组疗效差异有统计学意义(P<0.05).联合组1年总生存率(OS)为83.5%,2年OS为71.3%;CTOP组分别为78.3%,41.2%;两组患者的2年OS有显著性差异(P<0.05)。两组患者不良反应主要为轻中度骨髓抑制和胃肠道反应,不良反应发生率相近(P>0.05),均可耐受。结论利妥昔单抗联合化疗治疗弥漫型大B细胞淋巴瘤的临床缓解率较高,患者耐受良好且生存时间较长,应推荐作为首选方案。
Objective To evaluate the efficacy and toxicity of combination chemotherapy consisting of Rituximab and CTOP in patients with diffuse large B-cell lymphoma（DLBCL）.Methods A total of 36 patients with diffuse large B-cell lymphoma were divided into 2 groups： 18 received CTOP plus Rituximab（375mg/m2,1day before each course）（combination group）;18 received CHOP alone.Each course lasted 21 days.All cases were evaluated after 6 courses,All patients were followed up.Results The complete response rate and overall response rate were 55.6% and 88.9%,respectively,in the combination group,and 38.9% and 61.1%,respectively,in the CTOP group.The complete response rate in the combination group was significantly higher than that in the CTOP group（P〈0.05）.The 1-and2-year survival rates were 83.5%and71.3%,respectively,in the combination group and 78.3%and41.2%,respectively,in the CTOP group.The 2-year survival rate was significantly higher in the combination group than in the CTOP group（P〈0.05）.The major side effects in the two groups were mild to moderate myelosuppression and gastrointestinal toxicity,without a significant difference between the two groups（P〉0.05）.Conclusions Rituximab plus chemotherapy increased the therapeutic efficacy in clinic.The patients had well tolerance and longer survival time.Rituximab-containing chemotherapeutic regimens should be the first choice for DLBCL
出处
《医药论坛杂志》
2011年第9期78-80,82,共4页
Journal of Medical Forum
